Assessment of 10-year cardiovascular risk using the PREVENT-ASCVD score in patients with gout and comorbid diabetes mellitus
Main Article Content
Abstract
Assessing the risk of atherosclerotic cardiovascular disease using the PREVENT-ASCVD score in gout patients, particularly those with comorbid diabetes, is of significant importance for optimizing treatment strategies. We conducted a cross-sectional descriptive observational study on 68 patients diagnosed with gout according to the 2015 EULAR/ACR criteria and diabetes according to the 2023 ADA criteria, treated at the Musculoskeletal Center of Bach Mai Hospital from October 2025 to March 2026. Upon evaluating the 10-year cardiovascular risk using the PREVENT-ASCVD score, it was observed that 72.1% of the patients had intermediate and high cardiovascular risk. Factors associated with an increased cardiovascular risk included: advanced age, hypertension, reduced estimated glomerular filtration rate (eGFR), elevated HbA1c, prolonged duration of diabetes, and the number of acute gout attacks per year.
Article Details
Keywords
Gout, diabetes, cardiovascular risk, PREVENT-ASCVD
References
2. Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1-11. doi:10.1016/j.ejim.2020.07.006
3. Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 0(0). doi:10.1161/CIR.0000000000001423
4. Zhou H, Zhang Y, Zhou M, et al. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk Prediction. J Am Heart Assoc. 2025;14. doi:10.1161/JAHA.124.039454
5. Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789-1798. doi:10.1136/annrheumdis-2015-208237
6. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2022;46(Supplement_1):S19-S40. doi:10.2337/dc23-S002
7. Zhou H, Zhang Y, Zhou MM, et al. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk Prediction. J Am Heart Assoc. 2025;14(4):e039454. doi:10.1161/JAHA.124.039454
8. Nakahashi T, Tada H, Sakata K, Takamura M. Gout, Uric Acid, and Coronary Artery Disease. J Atheroscler Thromb. 2025;32(12):1471-1481. doi:10.5551/jat.RV22043
9. Thảo NLP, Ngọc NV, Liễu LT, Vân H, Quyên PTM. Khảo sát nguy cơ tim mạch trong 10 năm theo thang điểm ASCVD ở bệnh nhân Gút. Tạp chí Y học Việt Nam. 2025;557(2). doi:10.51298/vmj.v557i2.16684
10. So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639-647. doi:10.1038/nrrheum.2017.155